{"entity":{"id":"nct07415031","kind":"trial","name":"A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies","aka":[],"tldr":"A phase 2 trial of Adagrasib, Pembrolizumab, Cetuximab, Pemetrexed, Docetaxel and Oxaliplatin in advanced solid tumours, run by Mirati Therapeutics Inc., now recruiting.","summary":"A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies is a phase 2 interventional study registered as NCT07415031 by Mirati Therapeutics Inc., with 170 participants planned, started 2026-05-06 and due to reach its primary completion in 2028-02-16. Interventions recorded: Adagrasib, Pembrolizumab, Cetuximab, Pemetrexed, Docetaxel and Irinotecan.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07415031","url":"https://clinicaltrials.gov/study/NCT07415031"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["kras-inhibitors"],"targets":[],"drugs":["adagrasib","pembrolizumab","cetuximab","pemetrexed","docetaxel","oxaliplatin"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07415031","phase":"2","setting":"Solid Tumor Study for Long Term Treatment of Cancer Patients Who Have Participated in BMS Parent Studies Investigating Adagrasib (BMS-986503)","sponsor":"Mirati Therapeutics Inc.","participation":[{"nct":"NCT07415031","source":"https://clinicaltrials.gov/study/NCT07415031","fetchedAt":"2026-10-07T16:55:44.977Z","studySha256":"b889e986b84b5e6f72e803dd4f414f381959d4b78356b4b9d2b9bdbf53924aed","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-22","leadSponsor":"Mirati Therapeutics Inc.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":170,"enrolmentType":"ESTIMATED","siteCount":100,"recruitingSiteCount":16,"countries":["Australia","Belgium","Canada","China","France","Germany","Greece","Hungary","Israel","Italy","Japan","Netherlands","Poland","Portugal","Romania","Singapore","South Korea","Spain","United Kingdom","United States"]}],"started":"2026-05-06","startedType":"actual","enrolled":170,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07415031/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/"}],"drug":[{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/"},{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"},{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"oxaliplatin","kind":"drug","name":"Oxaliplatin","route":"/drugs/oxaliplatin/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}